Your AI-Trained Oncology Knowledge Connection!
In this article, we review the underlying biology and pharmacology behind lapatinib and summarize clinical trials with lapatinib. We also describe the ongoing clinical trials that use lapatinib as part of adjuvant and neoadjuvant therapy. These trials could change the standard of care in the next few years.
Measuring a woman's bone mineral density can provide additional information that may help to more accurately determine a woman's risk of developing breast cancer. That is the conclusion of a new study to be published in the September 1, 2008, issue of CANCER.
Mastectomy rates have been on the upswing at the Mayo Clinic in Rochester, Minnesota, and researchers cited MRI as a factor influencing the increase.
There is no doubt women at high risk for breast cancer need to be screened more aggressively than the general population. Thanks to extensive research-not to mention a nod from the American Cancer Society as a screening tool-MRI has leapt ahead of other imaging modalities as the preferred modality in a high-risk population.
Anthracyclines have been a cornerstone in the adjuvant treatment of breast cancer for more than 25 years and have well-established risks and benefits. But new molecular assays may make it possible to predict which women will benefit from this therapy, and new agents may offer better alternatives.
CHICAGO-The insulin sensitizer metformin may increase the response to neoadjuvant chemotherapy in diabetic patients with breast cancer, according to a retrospective study presented at ASCO 2008 (abstract 528).
Two years after her first mammogram the patient, EC, noticed swelling and skin changes in one breast. A bone scan, chest and abdomen CT, and PET scan were negative for metastatic spread, staging the cancer at IIIB.
CHICAGO-In recurrent or metastatic breast cancer, the addition of bevacizumab (Avastin) significantly improved progression-free survival over treatment with docetaxel (Taxotere) alone, European investigators reported at ASCO 2008 (abstract LBA-1011).
Positive data were reported from the first-ever randomized, multicenter, open-label phase III trial of the combination of two targeted agents, lapatinib (Tykerb) and trastuzumab (Herceptin), in women with HER2-positive metastatic breast cancer. The study results, which were presented at the annual ASCO meeting in Chicago, demonstrated a benefit from the combination (abstract 1015).
CHICAGO-For breast cancer patients whose tumors have become resistant to available agents, restoring the sensitivity to treatment is an important goal. Preclinical studies have suggested that drugs that inhibit the mTOR protein kinase-which acts as a central regulator of tumor cell division, cell metabolism, and blood vessel growth-may be able to do so.
A novel intraoperative breast cancer probe developed in Israel is showing significant promise in the reduction of repeat procedures in patients undergoing breast-conserving surgeries, according to a study presented at the American Society of Breast Surgeons Annual Scientific Meeting.
Using intensity-modulated radiation therapy for breast cancer patients after lumpectomy can reduce the incidence of acute dermatitis, compared with traditional whole-breast radiotherapy, reported Jean-Philippe Pignol, MD, of Sunnybrook Health Sciences Centre, Toronto, and colleagues.
Jay R. Harris, MD, will present the Gianni Bonadonna Breast Cancer Award lecture at the upcoming 2008 ASCO Breast Cancer Symposium being held September 5-7 in Washington DC. Dr. Harris is professor and chair of the Department of Radiation Oncology at the Dana-Farber Cancer Institute and the Brigham and Women’s Hospital at Harvard Medical School.
Breast Cancer is a unique effort in the world of breast cancer texts: Compact and concise, this 214-page book deals exclusively with breast cancer therapeutics, and strives to accomplish the difficult task of being as current as possible within the limited capabilities of the printed word in a rapidly evolving field. Dr. Seidman has assembled a distinguished group of authors, each of whom was assigned a topic, in the end covering all aspects of the medical oncologic scope of breast cancer treatment in one relatively short text. The book does not address issues of breast cancer epidemiology, screening, prevention, or surgical or radiation treatment-this was not the intent of this publication.
This practical review on the use of serum markers and circulating tumor cells (CTCs) focuses on the role of these assays in the management of patients with breast cancer and contains important information and perspectives for the practicing oncologist. The varying roles of these markers in early-stage and advanced disease are presented, and the implications in management are quite different in each setting.
Important therapeutic innovations within the past several years have resulted in only modest survival benefits for women with metastatic breast cancer. In this setting, cancer remains incurable and treatment is mainly palliative, involving judiciously applied multiple endocrine, chemotherapeutic, or biologic therapies in an attempt to induce a series of remissions and, ultimately, adequate palliation. At present, we lack both a consensus management algorithm and an ideal treatment model of specific subsets of women.
A large, international trial has shown that adding the targeted therapy bevacizumab (Avastin) to the chemotherapy drug docetaxel (Taxotere) slows disease progression in patients without prior chemotherapy for locally advanced or metastatic breast cancer. The results were presented by David Miles, md, a professor and medical oncologist at the Mount Vernon Cancer Centre in Middlesex, UK, and the study’s lead author (abstract LBA1011).
A large, international trial has shown that adding the targeted therapy bevacizumab (Avastin) to the chemotherapy drug docetaxel (Taxotere) slows disease progression in patients without prior chemotherapy for locally advanced or metastatic breast cancer. The results were presented by David Miles, md, a professor and medical oncologist at the Mount Vernon Cancer Centre in Middlesex, UK, and the study’s lead author (abstract LBA1011).
Researchers report that zoledronic acid (Zometa), a drug used to treat bone metastases and recently approved to treat osteoporosis, also lowers the risk of breast cancer recurrence in premenopausal patients with early-stage disease who have undergone surgery and are receiving ovarian suppression and hormone therapy. All women in this multicenter phase III trial had cancer that was estrogen-receptor– or progesterone-receptor–positive. The study was presented at the ASCO plenary session by lead author Michael Gant, md, professor of surgery at the Medical University of Vienna and the president of the Austrian Breast and Colorectal Cancer Study Group, or ABCSG (abstract LBA4).
Along with various imaging modalities, serologic tumor markers such as CA 15-3 and CA 27.29 have been used for decades to monitor treatment response in patients with metastatic breast cancer (MBC). Despite the frequent use of these markers, they lack high sensitivity and specificity for breast cancer progression. The prognostic significance of these markers remains indeterminate because of the conflicting outcome of many clinical trials. The circulating tumor cell (CTC) test has recently been studied in clinical trials in patients with MBC. Some of the studies showed that high levels of CTCs are correlated with poor survival in MBC. An intergroup trial is underway to determine the implication of changing treatment based on the CTC level. This article will discuss the current data on these markers, with special emphasis on the CTC test. The potential clinical utility of these markers will also be discussed.
CHICAGO-Zoledronic acid (Zometa) and adjuvant endrocrine therapy lowered the risk of disease recurrence in premenopausal women with early-stage breast cancer, according to the results of a major European trial. The bisphosphonate is already used to prevent bone loss in women undergoing adjuvant endocrine therapy for breast cancer.
The Cancer International Research Group (CIRG), a division of TRIO (Translational Research in Oncology) announced that, based on its study BCIRG 006, the US Food and Drug Administration (FDA) has approved a new regimen known as TCH (docetaxel [Taxotere] and carboplatin combined with trastuzumab [Herceptin]) for the adjuvant treatment of HER2-positive early breast cancer. The AC-TH regimen (doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab), also investigated in the BCIRG 006 study, received approval at the same time. This is the first taxane-based non–anthracycline-containing chemotherapy combined with trastuzumab to receive FDA approval.
Many women with a faulty breast cancer gene could be at greater risk of the disease due to extra risk-amplifying genes, according to research published recently in the American Journal of Human Genetics.
A novel biweekly dosing schedule of capecitabine (Xeloda) enabled safe delivery of higher daily doses in the treatment of advanced breast cancer, according to an investigational study published in the Journal of Clinical Oncology.
Genetic variations in the body’s receptor for vitamin D could increase the risk of breast cancer in postmenopausal women, according to a study published in the journal Breast Cancer Research.
